Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
17.11
-0.12 (-0.70%)
At close: Jun 27, 2025, 4:00 PM
17.25
+0.14 (0.82%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Sarepta Therapeutics Revenue
Sarepta Therapeutics had revenue of $744.86M in the quarter ending March 31, 2025, with 80.15% growth. This brings the company's revenue in the last twelve months to $2.23B, up 59.15% year-over-year. In the year 2024, Sarepta Therapeutics had annual revenue of $1.90B with 52.97% growth.
Revenue (ttm)
$2.23B
Revenue Growth
+59.15%
P/S Ratio
0.89
Revenue / Employee
$1,627,821
Employees
1,372
Market Cap
1.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
| Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
| Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
| Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
| Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
SRPT News
- 21 hours ago - Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (SRPT) - GlobeNewsWire
- 1 day ago - Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Sarepta Therapeutics, Inc. Securities and Sets a Lead Plaintiff Deadline of August 25, 2025 - GlobeNewsWire
- 2 days ago - SRPT SECURITIES: Lose Money on Sarepta Therapeutics, Inc. (NASDAQ:SRPT)? Contact BFA Law about the Pending Securities Fraud Investigation - GlobeNewsWire
- 2 days ago - Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny - Benzinga
- 3 days ago - FDA investigates patient deaths after treatment with Sarepta's gene therapy - Reuters
- 4 days ago - SRPT STOCK LOSS: Sarepta Therapeutics, Inc. Shareholders are Alerted of Ongoing Securities Fraud Investigation -- Contact BFA Law (NASDAQ:SRPT) - GlobeNewsWire
- 7 days ago - Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand - Benzinga
- 8 days ago - SRPT INQUIRY: Sarepta Therapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law (NASDAQ:SRPT) - GlobeNewsWire